Antitussive activity of the tachykinin NK1 receptor antagonist, CP-99994, in dogs

被引：18

作者：

Chapman, RW ^{[1
]}

House, A ^{[1
]}

Liu, F ^{[1
]}

Celly, C ^{[1
]}

Mei, H ^{[1
]}

Hey, JA ^{[1
]}

机构：

[1] Schering Plough Res Inst, Kenilworth, NJ 07033 USA

来源：

EUROPEAN JOURNAL OF PHARMACOLOGY | 2004年 / 485卷 / 1-3期

关键词：

cough; tachykinin NK1 receptor; CP-99994; (dog);

D O I：

10.1016/j.ejphar.2003.11.048

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

CP-99994 [(+)-(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine] is a selective tachykinin NK1 receptor antagonist that inhibits cough in guinea pigs and cats. This study examined the antitussive effects of CP-99994 in dogs produced by mechanical stimulation of the intrathoracic trachea. CP-99994 (10 mg/kg, p.o.) inhibited cough frequency by 52% at 2 h, 31% at 6 h and by 21% at 24 h. Cough amplitude was inhibited by 45% at 6 h but unchanged at 2 and 24 h after CP-99994. Plasma levels of CP-99994 were highest at 2 h (75 +/- 26 ng/ml) and fell to 22 +/- 6 ng/ml at 6 h. These results demonstrate antitussive activity of CP-99994 in dogs at a dose proven to antagonize tachykinin NK1 receptors in this species. (C) 2003 Elsevier B.V All rights reserved.

引用

页码：329 / 332

页数：4

共 50 条

[21] Effect of single point mutations of the human tachykinin NK1 receptor on antagonist affinity
Hawcock, AB
Lundstrom, K
Thomas, P
Naylor, A
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 120 : P328 - P328
[22] The tachykinin NK1 receptor antagonist GR205171 abolishes the retching activity of neurons comprising the central pattern generator for vomiting in dogs
Fukuda, H
Koga, T
Furukawa, N
Nakamura, E
Shiroshita, Y
NEUROSCIENCE RESEARCH, 1999, 33 (01) : 25 - 32
[23] Effect of single point mutations of the human tachykinin NK1 receptor on antagonist affinity
Lundstrom, K
Hawcock, AB
Vargas, A
Ward, P
Thomas, P
Naylor, A
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 337 (01) : 73 - 81
[24] Novel NK1 receptor antagonist
Terrett, N
DRUG DISCOVERY TODAY, 1997, 2 (11) : 501 - 501
[25] Effect of intrathecal pretreatment with the neurokinin receptor antagonist CP-99994 on the expression of naloxone-precipitated morphine withdrawal symptoms
Buccafusco, JJ
Shuster, LC
BRAIN RESEARCH BULLETIN, 1997, 43 (03) : 321 - 326
[26] A method to measure dual NK1/NK2-antagonist activity in dogs
Sherwood, JE
Young, S
Selig, W
Schilling, A
Kreutner, W
Egan, RW
Chapman, RW
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1998, 39 (02) : 97 - 101
[27] Disulfide bridge engineering in the tachykinin NK1 receptor
Elling, CE
Raffetseder, U
Nielsen, SM
Schwartz, TW
BIOCHEMISTRY, 2000, 39 (04) : 667 - 675
[28] Crystal structure of the human NK1 tachykinin receptor
Yin, Jie
Chapman, Karen
Clark, Lindsay D.
Shao, Zhenhua
Borek, Dominika
Xu, Qingping
Wang, Junmei
Rosenbaum, Daniel M.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (52) : 13264 - 13269
[29] PHARMACOLOGY OF GR203040, A POTENT AND SELECTIVE NONPEPTIDE TACHYKININ NK1 RECEPTOR ANTAGONIST
BEATTIE, DT
CONNER, HE
HAWCOCK, AB
PERREN, MJ
WARD, P
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 116 : P37 - P37
[30] The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret
Rudd, JA
Jordan, CC
Naylor, RJ
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 119 (05) : 931 - 936

← 1 2 3 4 5 →